Who
Daron Evans
CFO
Company insider
Files Form 4 as: CFO, Rezolute; CEO Specialty Renal Products, Nephros; Chief Financial Officer, Capricor Therapeutics.
In numbers
- Trades disclosed
- 128
- Buys
- 45
- Sells
- 0
- Bought
- $972K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 4 Mar 2008
- Last trade
- 21 Oct 2026
- Last filed
- 23 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Oct 2026filed 23 Oct 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code G | —16,000 at $0.00 | filing |
| 21 Oct 2026filed 23 Oct 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code G | —4,000 at $0.00 | filing |
| 21 Oct 2026filed 23 Oct 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code G | —4,000 at $0.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $15K3,062 at $4.99 | filing |
| 2 Jul 2026filed 7 Jul 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $15K3,062 at $4.99 | filing |
| 30 Mar 2026filed 31 Mar 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $29K10,000 at $2.85 | filing |
| 30 Mar 2026filed 31 Mar 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $29K10,000 at $2.85 | filing |
| 2 Mar 2026filed 4 Mar 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $34K11,438 at $2.99 | filing |
| 2 Mar 2026filed 4 Mar 2026 | RZLT RezoluteBiotechnology | SEC FORM 4 Code F | $34K11,438 at $2.99 | filing |
| 15 Dec 2025filed 15 Dec 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $71K40,000 at $1.77 | filing |
| 15 Dec 2025filed 15 Dec 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $4,4752,500 at $1.79 | filing |
| 15 Dec 2025filed 15 Dec 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $4,4752,500 at $1.79 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —63,000 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —107,000 at $0.00 | filing |
| 24 Jun 2025filed 24 Jun 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $20K5,000 at $4.05 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 10 Jun 2025filed 12 Jun 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 26 Mar 2025filed 28 Mar 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $29K10,000 at $2.89 | filing |
| 26 Mar 2025filed 28 Mar 2025 | RZLT RezoluteBiotechnology | SEC FORM 4 Bought | $29K10,000 at $2.88 | filing |
| 16 Feb 2025filed 19 Feb 2025 | RZLT Rezoluteoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
News
Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismRZLT · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Daron Evans; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.